Coronary artery disease is a complex trait — meaning it arises from the interplay of many genetic variants and environmental factors rather than a single gene mutation.
Coronary artery disease (CAD) has a substantial inherited component, but risk is polygenic and interacts strongly with environment.
Twin and family studies estimate the heritability of CAD at roughly 40–60%, with a first-degree relative having CAD roughly doubling an individual’s risk.
Nearly half of population‑level variation in risk is attributable to genetic differences.
Family history of premature CAD (first‑degree relative, male <55, female <65) roughly doubles or more the individual’s risk, independent of traditional risk factors.
Early-onset CAD (before age 55 in men, 65 in women) has a stronger heritable component.
A minority of cases follow clear Mendelian inheritance:
Familial Hypercholesterolemia (FH) is the most important.
Autosomal dominant mutations in LDLR (LDL receptor), APOB, or PCSK9 cause severely elevated LDL and premature atherosclerosis.
Heterozygous FH affects ~1 in 250 people; homozygous FH causes MI in childhood.
Other monogenic contributors include familial combined hyperlipidemia, familial hypertriglyceridemia, lipoprotein(a) elevations (LPA gene variants), and rare disorders like sitosterolemia.
The vast majority of inherited CAD risk is polygenic — driven by hundreds to thousands of common variants, each with small individual effect sizes.
Genome-wide association studies have identified >200 independent loci associated with CAD. Key genes and regions include:
9p21.3 — the strongest and most replicated CAD locus; contains CDKN2A/B and affects vascular smooth muscle proliferation
LPA — encodes apolipoprotein(a); high Lp(a) is a causal, largely genetically determined risk factor
Variants in *LDLR*, *APOB*, *PCSK9*, *NPC1L1*, *HMGCR* and others influence LDL levels and atherogenesis; monogenic disorders such as familial hypercholesterolemia confer very high lifetime risk.
GUCY1A3 — nitric oxide signaling
ABO — blood group gene; O blood group associated with lower risk
Polygenic Risk Scores (PRS): Aggregating variants across the genome into a PRS can identify individuals in the top percentile with risk comparable to monogenic FH (~3–4× elevated risk).
Genome‑wide association studies have identified hundreds of common variants, each with small effect, whose cumulative burden can be summarized as a polygenic risk score (PRS).
Rare damaging variants, such as those in LDLR can profoundly imperil health in affected persons, common risk alleles with small effects, appear to be more relevant at the population level.
Individuals in the highest PRS strata have several‑fold higher CAD risk than average, comparable to or exceeding the impact of many traditional risk factors.
The polygenic risk score for coronary artery disease among the persons in the top 5% of distribution is 3 to 5 times high as among persons in the middle quintiles of the population.
PRS is increasingly used clinically for risk stratification.
Genetic studies have confirmed several causal pathways for CVD
Lipid metabolism (LDL-C, HDL-C, Lp(a), triglycerides) Blood pressure regulation Platelet/thrombosis pathways Inflammation (e.g., IL6R, CRP loci) Vascular smooth muscle biology Endothelial function / nitric oxide signaling
Gene/Environment Interaction
Genetic predisposition is modifiable.
Individuals with high polygenic risk who maintain a healthy lifestyle (non-smoking, healthy diet, exercise, weight control) can reduce their lifetime CAD risk by ~50%, comparable to those with low genetic risk who live unhealthily.
Even in those with strong inherited risk, aggressive LDL lowering, BP control, smoking cessation, and exercise substantially reduce absolute event rates.
Genetic risk is probabilistic, not deterministic.
Behavioral and environmental factors (smoking, diet, physical inactivity, hypertension, diabetes) remain crucial; high genetic risk is markedly amplified by adverse lifestyle and attenuated by intensive risk‑factor control.
Family history remains a fundamental clinical risk factor
Cascade screening for FH is underutilized
Polygenic Risk Scores (PRS) is moving toward clinical utility in primary prevention decisions
Genetic discoveries have directly validated drug targets: PCSK9 inhibitors and LPA-lowering agents emerging directly from human genetics
Blood pressure and metabolic traits: Polymorphisms affecting renin–angiotensin signaling, sodium handling, insulin resistance, and obesity contribute to CAD susceptibility.
Vascular biology and thrombosis: Genes regulating endothelial function, smooth‑muscle proliferation, platelet reactivity, and coagulation (e.g., factors in nitric‑oxide signaling, prothrombotic pathways) modulate plaque formation and acute event risk.
Inflammation and immunity: Multiple SNPs in pathways governing cytokines, macrophage function, and adaptive immunity promote plaque initiation and instability via chronic vascular inflammation.
A detailed family history of age of onset, number and degree of affected relatives refines risk stratification and may trigger earlier or more intensive primary prevention and, in selected cases, genetic testing.